Applications of liquid chromatography-mass spectrometry based metabolomics in predictive and personalized medicine

Zhou, Juntuo; Zhong, Liang

doi:10.3389/fmolb.2022.1049016

Cited by 23 publications

(10 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolomics, as a fast-developing technique in biomedical research, can be used to identify novel biomarkers ( Kang et al, 2015b ) and as a promising predictive or personalized medicine research technique ( Zhou and Zhong, 2022 ). However, this systematic review has certain limitations, the most significant one is the challenge of comparing the metabolomic acquired across studies due to different limitation factors.…”

Section: Discussionmentioning

confidence: 99%

Metabolic fingerprinting of systemic sclerosis: a systematic review

Morales-González,

Galeano-Sánchez,

Covaleda-Vargas

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease, marked by an unpredictable course, high morbidity, and increased mortality risk that occurs especially in the diffuse and rapidly progressive forms of the disease, characterized by fibrosis of the skin and internal organs and endothelial dysfunction. Recent studies suggest that the identification of altered metabolic pathways may play a key role in understanding the pathophysiology of the disease. Therefore, metabolomics might be pivotal in a better understanding of these pathogenic mechanisms.Methods: Through a systematic review of the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Guidelines (PRISMA), searches were done in the PubMed, EMBASE, Web of Science, and Scopus databases from 2000 to September 2022. Three researchers independently reviewed the literature and extracted the data based on predefined inclusion and exclusion criteria.Results: Of the screened studies, 26 fulfilled the inclusion criteria. A total of 151 metabolites were differentially distributed between SSc patients and healthy controls (HC). The main deregulated metabolites were those derived from amino acids, specifically homocysteine (Hcy), proline, alpha-N-phenylacetyl-L-glutamine, glutamine, asymmetric dimethylarginine (ADMA), citrulline and ornithine, kynurenine (Kyn), and tryptophan (Trp), as well as acylcarnitines associated with long-chain fatty acids and tricarboxylic acids such as citrate and succinate. Additionally, differences in metabolic profiling between SSc subtypes were identified. The diffuse cutaneous systemic sclerosis (dcSSc) subtype showed upregulated amino acid-related pathways involved in fibrosis, endothelial dysfunction, and gut dysbiosis. Lastly, potential biomarkers were evaluated for the diagnosis of SSc, the identification of the dcSSc subtype, pulmonary arterial hypertension, and interstitial lung disease. These potential biomarkers are within amino acids, nucleotides, carboxylic acids, and carbohydrate metabolism.Discussion: The altered metabolite mechanisms identified in this study mostly point to perturbations in amino acid-related pathways, fatty acid beta-oxidation, and in the tricarboxylic acid cycle, possibly associated with inflammation, vascular damage, fibrosis, and gut dysbiosis. Further studies in targeted metabolomics are required to evaluate potential biomarkers for diagnosis, prognosis, and treatment response.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolic fingerprinting of systemic sclerosis: a systematic review

Morales-González,

Galeano-Sánchez,

Covaleda-Vargas

et al. 2023

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…Coupling with MS allows for reliable compound identification, making HPLC-MS suitable for high-throughput screening of a large number of samples. HPLC-MS can handle a wide range of compounds, including both nonpolar and polar metabolites, thermally unstable and/or non-volatile compounds, as well as high-molecular-weight compounds, such as complex lipids [ 13 , 14 , 26 ]. In comparison to direct injection methods in MS, HPLC-MS provides better specificity and lower limits of detection through chromatographic separation [ 23 ].…”

Section: Methods Landscapementioning

confidence: 99%

Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review

Demicheva,

Dordiuk,

Polanco Espino

et al. 2024

Metabolites

View full text Add to dashboard Cite

Blood metabolomics profiling using mass spectrometry has emerged as a powerful approach for investigating non-cancer diseases and understanding their underlying metabolic alterations. Blood, as a readily accessible physiological fluid, contains a diverse repertoire of metabolites derived from various physiological systems. Mass spectrometry offers a universal and precise analytical platform for the comprehensive analysis of blood metabolites, encompassing proteins, lipids, peptides, glycans, and immunoglobulins. In this comprehensive review, we present an overview of the research landscape in mass spectrometry-based blood metabolomics profiling. While the field of metabolomics research is primarily focused on cancer, this review specifically highlights studies related to non-cancer diseases, aiming to bring attention to valuable research that often remains overshadowed. Employing natural language processing methods, we processed 507 articles to provide insights into the application of metabolomic studies for specific diseases and physiological systems. The review encompasses a wide range of non-cancer diseases, with emphasis on cardiovascular disease, reproductive disease, diabetes, inflammation, and immunodeficiency states. By analyzing blood samples, researchers gain valuable insights into the metabolic perturbations associated with these diseases, potentially leading to the identification of novel biomarkers and the development of personalized therapeutic approaches. Furthermore, we provide a comprehensive overview of various mass spectrometry approaches utilized in blood metabolomics research, including GC-MS, LC-MS, and others discussing their advantages and limitations. To enhance the scope, we propose including recent review articles supporting the applicability of GC×GC-MS for metabolomics-based studies. This addition will contribute to a more exhaustive understanding of the available analytical techniques. The Integration of mass spectrometry-based blood profiling into clinical practice holds promise for improving disease diagnosis, treatment monitoring, and patient outcomes. By unraveling the complex metabolic alterations associated with non-cancer diseases, researchers and healthcare professionals can pave the way for precision medicine and personalized therapeutic interventions. Continuous advancements in mass spectrometry technology and data analysis methods will further enhance the potential of blood metabolomics profiling in non-cancer diseases, facilitating its translation from the laboratory to routine clinical application.

show abstract

“…There are several recent reviews that discuss why the results of numerous successful metabolomic studies have not yet seen their new diagnostics tests implemented into clinical practice [ 9 , 10 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 ]. All of them have reported that the pipeline of the biomarker development includes several key stages, consisting of discovery, validation, and the clinical translation of the finds.…”

Section: The Bottle Necks Of Personalized Metabolomicsmentioning

confidence: 99%

Current State and Future Perspectives on Personalized Metabolomics

et al. 2023

View full text Add to dashboard Cite

Metabolomics is one of the most promising ‘omics’ sciences for the implementation in medicine by developing new diagnostic tests and optimizing drug therapy. Since in metabolomics, the end products of the biochemical processes in an organism are studied, which are under the influence of both genetic and environmental factors, the metabolomics analysis can detect any changes associated with both lifestyle and pathological processes. Almost every case-controlled metabolomics study shows a high diagnostic accuracy. Taking into account that metabolomics processes are already described for most nosologies, there are prerequisites that a high-speed and comprehensive metabolite analysis will replace, in near future, the narrow range of chemical analyses used today, by the medical community. However, despite the promising perspectives of personalized metabolomics, there are currently no FDA-approved metabolomics tests. The well-known problem of complexity of personalized metabolomics data analysis and their interpretation for the end-users, in addition to a traditional need for analytical methods to address the quality control, standardization, and data treatment are reported in the review. Possible ways to solve the problems and change the situation with the introduction of metabolomics tests into clinical practice, are also discussed.

show abstract

Applications of liquid chromatography-mass spectrometry based metabolomics in predictive and personalized medicine

Cited by 23 publications

References 41 publications

Metabolic fingerprinting of systemic sclerosis: a systematic review

Metabolic fingerprinting of systemic sclerosis: a systematic review

Advances in Mass Spectrometry-Based Blood Metabolomics Profiling for Non-Cancer Diseases: A Comprehensive Review

Current State and Future Perspectives on Personalized Metabolomics

Contact Info

Product

Resources

About